top of page

BIO 2026: Sofinnova Investments' Managing Partner Jim Healy shares his (optimistic) take on the current state of biotech and the venture side of it

10 hours ago
1 min read

He says he sees generalist investors coming back to biotech for the first time in a while, which have been benefitting the IPO market and other areas of the sector. Plus, the areas he is focused on today and what it take to be a successful IPO candidate.

https://vimeo.com/1203638732

Coverage brought to you by

Recent Posts

EHA 2026: H.C. Wainwright Senior Biotech Analyst Mitchell Kapoor previews key EHA data from Legend and Incyte, and shares catalysts he is watching for after the conference

EHA 2026: H.C. Wainwright Senior Biotech Analyst Mitchell Kapoor previews key EHA data from Legend and Incyte, and shares catalysts he is watching for after the conference

At Nucleate UK's The Forum in London, former Novo Nordisk CSO Marcus Schindler reflects on the success of the GLPs and shares advice for biotech entrepreneurs in Europe

At Nucleate UK's The Forum in London, former Novo Nordisk CSO Marcus Schindler reflects on the success of the GLPs and shares advice for biotech entrepreneurs in Europe

At Nucleate UK's The Forum, early stage biotech investor Nirmesh Patel of Amino Collective says there is currently a bifurcation in fundraising between biotech co's with an AI angle and those without

At Nucleate UK's The Forum, early stage biotech investor Nirmesh Patel of Amino Collective says there is currently a bifurcation in fundraising between biotech co's with an AI angle and those without

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page